Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
OtherArticle

Quantitative CYP3A4 induction risk assessment using human hepatocytes complemented with pregnane X receptor (PXR)-activating profiles

Aynur Ekiciler, Wen Li Kelly Chen, Yan Bo, Alessandra Pugliano, Massimiliano Donzelli, Neil Parrott and Kenichi Umehara
Drug Metabolism and Disposition December 2, 2022, DMD-AR-2022-001132; DOI: https://doi.org/10.1124/dmd.122.001132
Aynur Ekiciler
1Pharmaceutical Sciences, F. Hoffmann-LaRoche, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: kenichi.umehara@roche.com
Wen Li Kelly Chen
2China Innovation Center of Roche, Roche Pharmaceutical Research and Early Development, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yan Bo
2China Innovation Center of Roche, Roche Pharmaceutical Research and Early Development, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alessandra Pugliano
3Roche Innovation Center Basel, Roche Pharmaceutical Research and Early Development, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Massimiliano Donzelli
3Roche Innovation Center Basel, Roche Pharmaceutical Research and Early Development, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Neil Parrott
4Roche, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenichi Umehara
5Pharmaceutical Sciences, Roche Pharmaceutical Research and Early Development, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: kenichi.umehara@roche.com
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Information

DMD-AR-2022-001132
DOI 
https://doi.org/10.1124/dmd.122.001132
PubMed 
36460477

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0090-9556
Online ISSN 
1521-009X
History 
  • Published online December 2, 2022.

Article Versions

  • You are currently viewing an Earlier version of this article (December 2, 2022 - 10:17).
  • View the most recent version of this article
Copyright & Usage 
Copyright © 2020 American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Aynur Ekiciler1,*,
  2. Wen Li Kelly Chen2,
  3. Yan Bo2,
  4. Alessandra Pugliano3,
  5. Massimiliano Donzelli3,
  6. Neil Parrott4, and
  7. Kenichi Umehara5,*
  1. 1Pharmaceutical Sciences, F. Hoffmann-LaRoche, Switzerland
  2. 2China Innovation Center of Roche, Roche Pharmaceutical Research and Early Development, China
  3. 3Roche Innovation Center Basel, Roche Pharmaceutical Research and Early Development, Switzerland
  4. 4Roche, Switzerland
  5. 5Pharmaceutical Sciences, Roche Pharmaceutical Research and Early Development, Switzerland
  1. ↵* Corresponding Author:
    Kenichi Umehara, Pharmaceutical Sciences, Roche Pharmaceutical Research and Early Development, Grenzacherstrasse 124, Basel, N/A, CH-4070, Switzerland. E-mail: kenichi.umehara{at}roche.com
  2. * Corresponding Author; email: kenichi.umehara{at}roche.com

Statistics from Altmetric.com

Article usage

Article usage: December 2022 to March 2023

AbstractFullPdf
Dec 202250745301
Jan 202320613169
Feb 202337525183
Mar 202330142105

Next
Back to top

In this issue

Drug Metabolism and Disposition: 51 (3)
Drug Metabolism and Disposition
Vol. 51, Issue 3
1 Mar 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Quantitative CYP3A4 induction risk assessment using human hepatocytes complemented with pregnane X receptor (PXR)-activating profiles
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherArticle

Evaluation of CYP3A4 induction incorporating PXR activation

Aynur Ekiciler, Wen Li Kelly Chen, Yan Bo, Alessandra Pugliano, Massimiliano Donzelli, Neil Parrott and Kenichi Umehara
Drug Metabolism and Disposition December 2, 2022, DMD-AR-2022-001132; DOI: https://doi.org/10.1124/dmd.122.001132

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
OtherArticle

Evaluation of CYP3A4 induction incorporating PXR activation

Aynur Ekiciler, Wen Li Kelly Chen, Yan Bo, Alessandra Pugliano, Massimiliano Donzelli, Neil Parrott and Kenichi Umehara
Drug Metabolism and Disposition December 2, 2022, DMD-AR-2022-001132; DOI: https://doi.org/10.1124/dmd.122.001132
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Metabolic enzymes in nintedanib metabolism
  • Mechanism of AO Inactivation by Hydralazine
  • Warfarin PBPK modeling with target binding
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics